Structure Therapeutics Inc. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
Structure Therapeutics Inc. (GPCR) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $872.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-08-06
- Structure Therapeutics Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-12-31 was $447.00K, a 14.32% increase year-over-year.
- Structure Therapeutics Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-09-30 was $0.00.
- Structure Therapeutics Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-12-31 was $391.00K.
- Structure Therapeutics Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-09-30 was $0.00.
- Structure Therapeutics Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $921.00K, a 45.73% increase from fiscal 2024.
- Structure Therapeutics Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $632.00K.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $872.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $447.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $447.00K derived: sum of 2 quarters · filed 2026-02-26 | $921.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $474.00K 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $474.00K 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $391.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $391.00K derived: sum of 2 quarters · filed 2026-02-26 | $632.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $241.00K 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $241.00K 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |